In this review, we show the expression levels of LXRα between tumor tissues and normal tissues via the Oncomine and the Tumor Immune Estimation Resource (TIMER) databases, focus on the role and mechanism of LXRα in various cancers, and discuss the conceivable performance of LXRα in cancer treatments. This evidence concerns the gene NR1H3 and neoplasm.